{"organizations": [], "uuid": "1dba62672a1e1f91e8d191fa050e3cc27747a41f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-feb-22-idUSL8N1QC12S", "country": "US", "domain_rank": 408, "title": "Swiss stocks - Factors to watch on Feb 22", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.727, "site_type": "news", "published": "2018-02-22T14:36:00.000+02:00", "replies_count": 0, "uuid": "1dba62672a1e1f91e8d191fa050e3cc27747a41f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-feb-22-idUSL8N1QC12S", "ord_in_thread": 0, "title": "Swiss stocks - Factors to watch on Feb 22", "locations": [], "entities": {"persons": [{"name": "julius baer", "sentiment": "none"}], "locations": [{"name": "zurich", "sentiment": "none"}, {"name": "polyphor", "sentiment": "none"}, {"name": "zurich", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "partners group", "sentiment": "none"}, {"name": "santhera pharmaceuticals", "sentiment": "none"}, {"name": "novartis", "sentiment": "none"}, {"name": "cembra money bank", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH, Feb 22 (Reuters) - The Swiss blue-chip SMI was seen opening 0.8 percent lower at 8,922 points on Thursday, according to premarket indications by bank Julius Baer .\nHere are some of the main factors that may affect Swiss stocks on Thursday:\nNOVARTIS The Swiss pharma company said a study showed its treatment once-daily Ultibro Breezhaler improved the cardiac function in chronic obstructive pulmonary disease patients with lung hyperinflation.\nFor more, click on\nCOMPANY STATEMENTS * Cembra Money Bank said its net income rose 1 percent to 144.5 million Swiss francs in 2017. It proposed to increase its dividend to 3.55 francs per share.\n* Partners Group sait it raised a total of 3 billion euros for its latest direct private infrastructure offering.\n* Santhera Pharmaceuticals said it increased its share capital to pay the upfront consideration for the license to develop and commercialize a clinical stage candidate for pulmonary diseases obtained from Polyphor.\nECONOMY * Swiss industrial orders for Q4 are due at 0815 GMT.\nReporting by Zurich newsroom\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T14:36:00.000+02:00", "crawled": "2018-02-23T15:48:24.010+02:00", "highlightTitle": ""}